Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysisResearch in context

Summary: Background: Recent clinical trials have shown that molecularly-guided treatments can improve survival in patients with cancers of unknown primary (CUP). However, the feasibility and clinical benefit of these treatments for CUP in a real-life setting remain uncertain. In France, a national...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Célia Dupain, Nicolas Jacquin, Aurélien Latouche, Zoé Nevière, Pierre Gestraud, Abderaouf Hamza, Kenza Nedara, Vincent Cockenpot, Janick Selves, Yves Allory, Laëtitia Chanas, Maud Milder, Isabelle Soubeyran, Hélène Blons, Anna Patrikidou, Axel de Bernardi, Julien Masliah-Planchon, Odette Mariani, Etienne Rouleau, Fabienne Escande, Sandrine Boyault, Pierre Saintigny, Florence de Fraipont, Pierre Blanc, Jennifer Wong, Camille Tlemsani, Isabelle Guillou, Julie Flavius, Noemie Fuentealba, Maud Kamal, Ivan Bièche, Nicolas Servant, Christophe Le Tourneau, Sarah Watson
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2026-01-01
Σειρά:	The Lancet Regional Health. Europe
Θέματα:	Cancer of unknown primary Multidisciplinary tumour board Next generation sequencing Personalized medicine Survival
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2666776225003163
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!